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Abstract
The neuraminidase inhibitor oseltamivir is currently used for treatment of patients infected with the pandemic A/H1N1
(pH1N1) influenza virus, although drug-resistant mutants can emerge rapidly and possibly be transmitted. We describe the
characteristics of a pair of oseltamivir-resistant and oseltamivir-susceptible pH1N1 clinical isolates that differed by a single
change (H274Y) in the neuraminidase protein. Viral fitness of pH1N1 isolates was assessed in vitro by determining
replication kinetics in MDCK a2,6 cells and in vivo by performing experimental infections of BALB/c mice and ferrets. Despite
slightly reduced propagation of the mutant isolate in vitro during the first 24 h, the wild-type (WT) and mutant resistant
viruses induced similar maximum weight loss in mice and ferrets with an identical pyrexic response in ferrets (AUC of 233.9
and 233.2, P=0.5156). Similarly, comparable titers were obtained for the WT and the mutant strains on days 1, 3, 6 and 9
post-infection in mouse lungs and on days 1–7 in ferret nasal washes. A more important perivascular (day 6) and pleural
(days 6 and 12) inflammation was noted in the lungs of mice infected with the H274Y mutant, which correlated with
increased pulmonary levels of IL-6 and KC. Such increased levels of IL-6 were also observed in lymph nodes of ferrets
infected with the mutant strain. Furthermore, the H274Y mutant strain was transmitted to ferrets. In conclusion, viral fitness
of the H274Y pH1N1 isolate is not substantially altered and has the potential to induce severe disease and to disseminate.
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Introduction
The novel influenza A (H1N1) virus was initially detected in
Mexico and California in April 2009 and then officially became
the first pandemic influenza virus of the 21
st century on June 11,
2009 [1,2]. Most confirmed cases of pandemic A/H1N1 (pH1N1)
infection have been characterized so far by self-limited flu-like
symptoms and signs although a significant proportion of infected
patients also presented with vomiting and diarrhea [2]. A minority
of cases, notably those involving pregnant women, have been
associated with a more severe clinical outcome leading to intensive
care admission and death [3,4,5]. Mouse, ferret and non-human
primate studies have indicated that pH1N1 isolates replicate more
efficiently and produce more severe pathological lesions in the
lungs than recent human A/H1N1 viruses [6,7,8]. Seroprevalence
studies have indicated that children were initially serologically
naı ¨ve to the novel pH1N1 strain whereas some degree of pre-
existing immunity to this virus existed in the elderly population
[6,9,10].
Antivirals are the cornerstone of treatment for severe influenza
cases requiring hospitalization and can also be used as prophy-
lactic agents in high-risk individuals. Early reports demonstrated
that pH1N1 strains were resistant to the adamantanes due to a
S31N mutation in the M2 gene but remained susceptible to
neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir
[6,11]. However, oseltamivir resistance has been on the rise in
recent seasonal influenza A/H1N1 viruses. Indeed, during the
2008–09 influenza season, almost all characterized influenza A/
Brisbane/59/2007-like (H1N1) strains from North America and
Europe were resistant to oseltamivir due to a H274Y (N2
numbering) mutation in the neuraminidase (NA) gene
[12,13,14]. The sudden and large dissemination of this mutant
A/H1N1 virus occurred in the apparent absence of antiviral
pressure suggesting that it had no impairment in viral fitness. This
drug resistance mutation has also been reported in some A/H5N1
viruses [15,16] and, more recently, in several pH1N1 strains
recovered from both immunocompromised and immunocompe-
tent subject [17,18,19,20]. We recently reported the emergence of
such an oseltamivir-resistant H274Y mutant in a familial cluster of
pH1N1 infections [21]. In this outbreak, we identified a drug-
susceptible virus recovered before therapy from a 13-year old boy
and a drug-resistant virus collected a few days later from his father
who was receiving oseltamivir prophylaxis. We now describe the in
vitro and in vivo replicative characteristics of the drug-resistant and
wild-type (WT) viruses isolated from this outbreak.
Results
As shown in Table 1, the pH1N1 isolate from the index case
collected before oseltamivir therapy (A/Que ´bec/147023/2009-
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the contact case recovered during post-exposure oseltamivir
prophylaxis (A/Que ´bec/147365/2009-H274Y) was resistant to
oseltamivir and peramivir. Both isolates were susceptible to
zanamivir and A-315675 similarly to 20 other pH1N1 isolates
collected from untreated subjects in the same period. The pattern
of NAI resistance of the pH1N1 H274Y mutant was similar to that
of another H274Y mutant from a seasonal A/H1N1 strain (A/
Brisbane/59/2007-H274Y). A pH1N1 H274Y recombinant
mutant virus generated from an unrelated pH1N1 strain also
exhibited high levels of resistance to oseltamivir and peramivir but
remained susceptible to zanamivir and A-315675 (Table 1).
Sequence analysis of the original clinical isolates revealed the
presence of only one substitution (H274Y; N2 numbering) in the
NA gene of the contact case (GenBank accession number
FN434454) compared to that of the index case (accession number
FN434445). There was no change in the remaining 7 segments
between these two strains (accession number FN434440 to
FN434447 for the index case virus and FN434448 to FN4456
for the contact case virus). Phylogenetic analysis of the NA and HA
genes showed that the two pH1N1 isolates described in this study
were closely related to pH1N1 strains identified in North America,
Europe and Asia (data not shown). The viral populations in the
two clinical isolates were homogenous as 100% (16/16) of clones
from the index case had the H274 sequence whereas 100% (16/
16) of clones from the contact case harboured the 274Y sequence.
In vitro experiments performed in MDCK cells expressing the
a2,6 sialic acid receptor indicated that the oseltamivir-resistant
pH1N1 isolate replicated less efficiently than the WT pH1N1
during the first 24 h. However, there was no significant difference
in viral titers subsequently i.e. from 36 to 72 h (Figure 1). The two
pH1N1 isolates produced lower viral titers than seasonal A/H1N1
viruses (A/Brisbane/59/2007) including both a WT and a H274Y
mutant at 36 and 48 h. Thus, the H274Y mutation resulted in
either no impairment or only initial reduction in replicative
capacities when inserted in seasonal and pandemic A/H1N1
backgrounds, respectively. Of note, the two pH1N1 viruses
produced less well defined viral plaques on a2,6-transfected
MDCK cells compared to seasonal strains (data not shown).
Two separate mouse experiments were conducted to assess
weight loss, clinical signs, viral titers (on days 3 and 6 in the first
experiment and on days 1, 6 and 9 in the second experiment) and
histopathological changes. In the first experiment, the WT and
oseltamivir-resistant pH1N1 isolates induced similar maximum
weight loss, which peaked on day 8 at 16.3% for both groups
(P=0.81) although there was a more pronounced weight loss from
days 3 to 7 with the mutant strain (Figure 2). In the second
experiment, more weight loss was induced after infection with the
H274Y mutant from days 3 to 8. By day 12, all mice from the two
experiments had returned to their initial weight with no mortality.
Lung viral titers, which were determined on days 1, 3, 6 and 9
post-infection, did not significantly differ between the WT and
H274Y mutant viruses when assessed by quantitative viral culture
(Figure 3) and real-time RT-PCR (Figure S1). Importantly, there
was no unexpected change in the NA sequence of viruses
recovered from lungs of euthanized mice.
Transcript levels for various cytokines/chemokines (KC
[CXCL1], MCP-1 [CCL2], MIP-1a, IFN-c, IL-4, IL-5, IL-6
and IL-10) were determined in lungs of infected mice on days 1, 6
and 9 post-infection. All cytokines/chemokines were equally
Table 1. Susceptibility profiles of pH1N1 isolates, A/Brisbane/59/2007-like A/H1N1 isolates of the 2009 season, and recombinant
pH1N1 viruses as tested by NA inhibition assays.
Oseltamivir IC50
in nmol/L ± SD
a
Zanamivir IC50
in nmol/L ± SD
a
Peramivir IC50
in nmol/L ± SD
a
A-315675 IC50
in nmol/L ± SD
a
Seasonal A/H1N1 isolates of the
2009 season (n=33)
541.9673.17 0.3660.2 33.168.1 1.7160.31
pH1N1 isolates of the 2009 season (n=20) 0.4360.17 0.1260.04 0.0860.03 0.1760.04
A/Que ´bec/147023/2009-WT (pH1N1) 0.2760.01 (1) 0.1860.01 (1) 0.0860.01 (1) 0.0860.004 (1)
A/Que ´bec/147365/2009-H274Y (pH1N1) 423.01620 (1566) 0.1260.01 (0.6) 11.5162.7 (144) 0.2860.07 (3.5)
A/Brisbane/59/2007-WT (seasonal) 0.5360.1 (1) 0.360.04 (1) 0.160.03 (1) 0.3260.12 (1)
A/Brisbane/59/2007-H274Y (seasonal) 751.12693 (1417) 0.560.2 (1.7) 34.569.2 (345) 0.8260.3 (2.6)
Recombinant-WT (pH1N1) 0.4660.01 (1) 0.1560.01 (1) 0.0960.01 (1) 0.260.03 (1)
Recombinant-H274Y (pH1N1) 451.9626 (982) 0.1460.01 (1) 23.6365.5 (268) 0.2860.01 (1.4)
aIC50 values were determined in triplicate experiments. Mean IC50 6 standard deviation (SD) are shown. Fold increases in IC50 values compared to the respective WT
virus are shown in parentheses.
Abbreviations: pH1N1, pandemic A/H1N1 virus; WT, wild-type; NA, neuraminidase.
doi:10.1371/journal.ppat.1001015.t001
Author Summary
During the 2009 pandemic of the novel A/H1N1 (pH1N1)
virus, the World Health Organization recommended
oseltamivir as first-line agent for treatment of patients
with severe infections leading to hospitalization and for
those with underlying diseases predisposing to pulmonary
complications. Oseltamivir-resistant isolates started to
emerge at the end of June 2009 with now more than
100 strains reported worldwide including a few outbreaks
where transmission of resistant viruses may have occurred.
We characterized the fitness of a pair of oseltamivir-
susceptible and oseltamivir-resistant strains emerging
from the same familial cluster and that differed by only a
single change (H274Y) in the neuraminidase protein. We
found that the drug-resistant (mutant) virus was at least as
virulent as the drug-susceptible (wild-type) virus in mice
and ferrets. Based on these data, we believe that the
H274Y pH1N1 mutant strain has the potential to
disseminate in the population and to eventually replace
the susceptible strain, a phenomenon that has been
already observed with seasonal A/Brisbane/59/2007-like
(H1N1) viruses.
Oseltamivir-Resistant pH1N1 Virulence
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(Figure S2), with the exception of increased expression of IL-6 and
KC levels on day 1, following infection with the H274Y mutant
virus (Figure 4).
Both pH1N1 isolates induced significant pulmonary inflamma-
tion including peribronchial, interstitial, perivascular, alveolar and
pleural inflammation that peaked on day 6 post-infection (Figure
S3). There was significantly more perivascular (day 6) and pleural
(days 6 and 12) inflammation visualized in the lungs of mice infected
with the H274Y mutant compared to the WT virus (Figure 5). A
mild to moderate vascular congestion was observed in both groups
of mice although pulmonary oedema was not noted in any mice.
Inflammatory cellular infiltration was characterized by both acute
(neutrophilic) and chronic (lymphohistiocytic) infiltrates in all mice.
Thus, mouse experiments indicated that the mutant pH1N1 isolate
induced more pronounced weight loss than the WT virus which
correlated with increased expression of IL-6 and KC and more
significant lung inflammation despite similar lung viral titers.
Intranasal inoculation of ferrets with the WT and H274Y
mutant pH1N1 isolates resulted in a strong anti-A/California/07/
2009 serum antibody response on day 14 (hemagglutination
inhibition reciprocal geometric mean titers went from ,20 to
4208 and from ,20 to 3135, respectively). Notably, all ferrets had
preexisting HI antibodies against seasonal A/H1N1 (A/Brisbane/
59/07) but titers were similar in the two groups of ferrets pre- and
post-infection (Table S1). A pyrexic response was seen between
days 2 and 8 post-inoculation (Figure 6). Interestingly, temperature
curves were biphasic with a major peak on days 2–3 and another
lower peak on days 5–6 in both groups of ferrets. The area under
the curve (AUC) of temperatures over the course of the 14-day
experiment was similar for both groups of ferrets i.e.
233.960.5787 for the WT and 233.260.8669 for the H274Y
mutant (P=0.5156). Also, the mean percentage of body weight
loss over time was not significantly different in animals infected
with the WT or the H274Y mutant virus (Figure S4). The
maximum weight loss (day 7 and day 3) was 7.54% and 4.15% for
the WT and H274Y mutant viruses, respectively (P=0.0515). By
the end of the 14-day observation period, the ferrets had returned
to their initial weight with no mortality.
Viruses could be recovered from nasal wash of ferrets up to 7 days
post-infection with a peak on day 2 post-infection (Figure 7). Viral
titers did not significantly vary at any time points when comparing the
two groups of ferrets. Increased levels of IL-6, IL-12 and IFN-c
mRNA were observed in retropharyngeal lymph nodes of ferrets
infected with theH274YmutantcomparedtotheWTonday 14with
ratios of 1.174, 1.38 and 1.183, respectively (not shown). Expression
of IL-2 was decreased in ferrets infected with the mutant virus
compared to the WT with a ratio of 0.8. Thus, ferret experiments
showed no significant differences in clinical parameters (temperature
and weight) and viral titers in the upper respiratory tract for the WT
Figure 1. Replicative capacities of wild-type (WT) and H274Y mutant isolates of pH1N1 and seasonal A/H1N1 viruses. Viral titers were
determined at the indicated time points from supernatants of ST6Gal I-expressing MDCK cells infected with pH1N1 A/Que ´bec/147023/2009 (WT),
pH1N1 A/Que ´bec/147365/2009 (H274Y mutant), A/Brisbane/59/07-like (WT) and A/Brisbane/59/07-like (H274Y mutant) isolates at a multiplicity of
infection (MOI) of 0.001. Mean viral titers 6 SD from triplicate experiments were determined by using standard plaque assays.
* P,0.05 between the
WT and H274Y pH1N1 viral titers.
doi:10.1371/journal.ppat.1001015.g001
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5610
5 PFUs of either WT pH1N1 (A/Que ´bec/147023/2009) or oseltamivir-resistant H274Y mutant (A/Que ´bec/147365/2009) isolate. Three to four mice
per group were sacrificed on days 1, 3, 6 and 9 for determination of lung viral titers, which were reported as TCID50 per gram of lung.
doi:10.1371/journal.ppat.1001015.g003
Figure 2. Weight loss of mice infected with wild-type (WT) or H274Y mutant isolates of pH1N1. The weight loss of mice was evaluated in
two groups of 15 mice (infected with the WT and H274Y mutant isolate) over a period of 14 days. These experiments were performed twice and
reported as #1 and #2 on the graph. * P,0.05 between the WT and H274Y pH1N1 weight losses.
doi:10.1371/journal.ppat.1001015.g002
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and IFN-c) were specifically upregulated in lymph nodes of ferrets
infected with the H274Y mutant.
A limited transmission study was conducted in ferrets and it
demonstrated that the H274Y mutant strain was transmitted from
ferrets experimentally infected intranasally to ferrets placed in the
same cage 24 h after infection. All contact ferrets seroconverted
for A/California/07/2009 when tested 14 days after contact
(hemagglutination inhibition reciprocal geometric mean titers
went from ,20 to 993). All contact ferrets also shed virus and had
a mean peak viral titer of 8.32610
4 PFU/ml in their nasal washes.
Discussion
Oseltamivir, the most frequently used NAI, is recommended for
treatment of patients with severe pH1N1 infections leading to
Figure 4. Lung IL-6 and KC expression in mice infected with wild-type (WT) or H274Y mutant isolates of pH1N1. Mice were infected
intranasally with 5610
5 PFUs of either WT pH1N1 isolate (A/Que ´bec/147023/2009) or oseltamivir-resistant H274Y mutant (A/Que ´bec/147365/2009).
Three to four mice per group were respectively sacrificed on days 1, 6 and 9 for determination of lung IL-6 and KC transcripts.
* P,0.05, ** P,0.0001
between the WT and H274Y cytokine transcript levels.
doi:10.1371/journal.ppat.1001015.g004
Figure 5. Lung histopathology of mice infected with wild-type (WT) or H274Y mutant isolates of pH1N1. Groups of mice were
euthanized on days 3, 6 and 12 post-infection and one pulmonary lobe was removed and fixed with 10% formalin. Thin sections of paraffin-
embedded lung tissues were cut and stained with hematoxylin and eosin. The degree of lung inflammation (mean histopathological score) was
evaluated for bronchial, peribronchial, perivascular, interstitial, pleural and intra-alveolar inflammation.
* P,0.05 between the WT and H274Y lung
histopathological scores.
doi:10.1371/journal.ppat.1001015.g005
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at risk of complications. We have recently described the rapid
emergence of oseltamivir resistance in a family cluster of pH1N1
infection due to the H274Y NA mutation [21], and now report on
the viral fitness of this mutant in vitro and in vivo. Despite slightly
reduced propagation of the mutant isolate in vitro during the first
24 h of infection compared to the original WT virus, both isolates
replicated as efficiently in the lower respiratory tract of mice and in
the upper respiratory tract of ferrets inducing similar maximum
weight loss and pyrexic response between days 2 and 8 post-
infection. Interestingly, the H274Y NA mutant induced a slightly
more pronounced weight loss than the WT virus in mice, and this
observation correlated with increased production of IL-6 and KC
and a more important pulmonary inflammation involving the
perivascular (day 6) and pleural (days 6 and 12) compartments.
Previous studies have demonstrated that oseltamivir resistance
results from subtype-specific NA mutations [15]. In influenza
viruses of the N1 subtype, including seasonal A/H1N1 viruses and
avian A/H5N1 strains, oseltamivir resistance is mainly conferred
by the H274Y (N2 numbering) mutation [16,22,23]. This
mutation has also been recently detected in pH1N1 viruses
[17,18,19,20,21]. The larger tyrosine residue at codon 274
prevents the re-orientation of glutamic acid at position 276 within
the catalytic site, which is required to accommodate the bulky side
chain of oseltamivir but not zanamivir [24]. In agreement with
previously-described seasonal A/H1N1 viruses containing the
H274Y NA mutation, our oseltamivir-resistant pH1N1 mutant
showed cross-resistance to peramivir, a parenteral NAI that is in
phase 3 clinical trials [15,25] and also readily available through an
emergency access program [26]. On the other hand, our
phenotypic findings demonstrate an interesting potential for
inhaled zanamivir and the investigational orally-available A-
322278 NAI compound (the prodrug of A-315675) [27], as
alternative agents for treatment of oseltamivir-resistant pH1N1
infections.
The impact of mutations conferring NAI resistance on viral
fitness and transmissibility may vary depending on the genetic
background of influenza viruses. In the N1 subtype, the H274Y
mutation has been initially reported as impairing the viral fitness of
older seasonal strains such as A/New Caledonia/20/99-like and
A/Texas/36/91 when evaluated in the ferret model [28,29].
However, transmission of the H274Y mutant strain was
documented in ferrets [28]. More recently, our group showed
that the same mutation had a different effect, i.e. it was associated
with conserved viral fitness in the seasonal A/Brisbane/59/2007
(H1N1) background when assessed both in vitro and in ferrets [30].
In the present study, the replication of the pH1N1 H274Y mutant
was initially impaired in vitro compared to the WT virus but viral
titers were virtually identical on days 2 and 3 post-infection. The
two pH1N1 isolates replicated less efficiently (lower titers and
reduced plaque formation) than the recent WT and H274Y
mutant A/Brisbane/59/2007 strains in ST6Gal I-expressing
MDCK cells, which may indicate a greater affinity of the seasonal
strain for a2,6 sialic acid receptors.
Figure 6. Body temperature of ferrets infected with wild-type (WT) or H274Y mutant isolates of pH1N1. Body temperatures were
recorded by implanted thermometers during 14 days post-inoculation in groups of 4–5 ferrets infected with WT (A/Que ´bec/147023/2009) or
oseltamivir-resistant H274Y mutant (A/Que ´bec/147365/2009) pH1N1 isolates.
doi:10.1371/journal.ppat.1001015.g006
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models for studying WT pH1N1 infection. For instance, Itoh et al.
[6] and Maines et al. [7] observed significant weight loss in BALB/
c mice associated with efficient viral replication in lungs when an
intranasal inoculum $10
4 plaque forming units (PFUs) was used.
Some mice even died from a viral challenge consisting of 10
6 PFUs
[6]. Those results indicate that pH1N1 strains can replicate
efficiently in mice in contrast to most seasonal A/H1N1 strains.
The selective replication of pH1N1 virus in the BALB/c mouse
model without prior animal adaptation is reminiscent of features
described for highly pathogenic A/H5N1 viruses and the 1918
Spanish flu virus although they are generally less severe with
pH1N1 [31,32]. In agreement with these reports, we observed that
pH1N1 can efficiently infect BALB/c mice inducing weight loss,
high viral lung titers and also significant pulmonary histopatho-
logical changes. Moreover, we now report that the H274Y pH1N1
mutant virus is clearly as fit as the WT virus in this animal model.
In fact, more weight loss was induced by the H274Y mutant
compared to the WT virus during the first 7–8 days post-infection
although all mice eventually returned to their initial weight. On
the other hand, we found no significant differences in lung viral
titers between the two groups of mice when assessed on days 1, 3, 6
and 9. The more prounounced weight loss observed with the
mutant strain compared to the WT virus was confirmed in two
separate experiments using similar viral inoculum (as confirmed by
back titration) and unaltered viral genomes (as confirmed by
sequencing the virus from lungs of euthanized mice). These
important clinical signs correlated with slightly more severe
histopathological changes observed in lungs of mutant-infected
mice in particular on days 6 and 12 post-infection and more
specifically in the perivascular and pleural compartments.
Altogether, those results suggest that the H274Y pH1N1 mutant
isolate stimulated a more important inflammatory response in
mice compared to WT virus, which could be due to rapid
induction of IL-6 and KC in the former. It has been reported for
different influenza viruses that the early secretion of pro-
inflammatory cytokines was associated with the development of
pulmonary inflammation at a later stage [33] as shown here for
pH1N1. Interestingly, the H274Y mutant also induced preferen-
tial expression of IL-6, IL-12 and IFN-c in the retropharyngeal
lymph nodes of ferrets compared to the WT virus. In humans, IL-
6 has been shown to be the first cytokine to appear in nasal wash of
infected individuals and the one likely responsible for much of the
clinical symptoms [34,35,36]. Additional studies are required to
assess the mechanism leading to increased IL-6 levels in animals
infected with the H274Y NA mutant.
As shown in some but not all studies [6,7,8], our two pH1N1
isolates induced a strong pyrexic response (increased in temper-
ature of 2uC) and slight weight loss (3–7%) in ferrets. Interestingly,
we noticed a biphasic temperature curve for both groups of ferrets.
The first and major febrile peak correlated with maximum viral
titers and the second minor increase in temperature seen on day 6
might be due to cytokine release. Similar biphasic temperature
curves were also seen in ferrets infected with WT A/H5N1 viruses
(data not shown). Previous investigators have shown that both
pH1N1 and seasonal A/H1N1 strains replicate to similar levels in
the upper respiratory tract of ferrets but only the former could
replicate to high levels in the lungs [6,7,8]. As for the comparison
of the WT and mutant pH1N1 isolates, we found no significant
difference in nasal wash viral titers of ferrets as determined at
several time points but did not assess lung viral titers.
Among the strengths of our study is the use of two clinical
isolates from the same familial cluster that differed by a single a.a.
and that were only passaged twice before animal studies. Also, the
use of two different animal models to characterize the virulence of
these strains and the relatively similar results observed in both of
them reinforce our conclusions. A limitation of our study is the
incomplete assessment of the transmissibility of our pH1N1 strains.
Figure 7. Nasal wash viral titers of ferrets infected with wild-type (WT) or H274Y mutant isolates of pH1N1. Viral titers were determined
daily over 14 days post-inoculation from nasal washes of ferrets infected with WT (A/Que ´bec/147023/2009) or oseltamivir-resistant H274Y mutant (A/
Que ´bec/147365/2009) pH1N1 isolates. Mean viral titers 6 SD from triplicate experiments were determined by using standard plaque assays.
doi:10.1371/journal.ppat.1001015.g007
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transmitted efficiently via aerosol or respiratory droplets [6,8]. We
report here that the H274Y mutant could be transmitted by
contact to uninfected ferrets but did not compare the efficiency of
transmission with the WT strain and neither evaluated aerosol
transmission. A confounder is the seropositive status of our ferrets
for the seasonal A/Brisbane/59/2007 (H1N1) strain before
challenge with pH1N1 viruses. In guinea pigs, preexisting
immunity to recent seasonal A/H1N1 viruses reduced viral load
and transmission of pH1N1 [37] whereas a ferret study with the
seasonal A/H1N1 vaccine showed little protection from challenge
with pH1N1 [38]. Although preexisting antibody levels against an
heterologous strain could have an effect on pathogenicity and
transmission of pH1N1, the geometrical mean antibody titers were
similar for our two groups of ferrets, which should not change our
conclusion about the relative pathogenicity of the H274Y mutant
compared to the WT strain. Furthermore, we found similar results
with the two strains in non-immune mice. Finally, our animal
results may not be completely relevant to humans due to
differences in distribution of HA cell receptors.
In summary, although some slight differences were observed in
the two animal models, we can conclude that the H274Y pH1N1
mutant seems as virulent as the WT isolate with no obvious
impairment in viral fitness. Although reports of limited person-to-
person transmission in several epidemiological settings have been
observed [39], currently no evidence of widespread dissemination
of oseltamivir-resistant pH1N1 has been reported indicating the
continued value of this drug for treatment of severe cases. Other
H274Y pH1N1 mutants (with different genetic backgrounds)
should be studied in terms of virulence and efficiency of
transmission to confirm our conclusions. In the meantime, careful
monitoring of the H274Y mutation during pH1N1 outbreaks is
mandatory to rapidly identify transmission events that could lead
to large-scale dissemination of an oseltamivir-resistant pH1N1
strain.
Materials and Methods
Viruses
The two pH1N1 viruses that differed by only a single mutation
in the NA gene were recovered from a family cluster of infection
and passaged twice in ST6Gal I-expressing MDCK cells before
testing. The two seasonal A/H1N1 viruses were collected in 2007
and passaged 3 times before testing.
Drug susceptibility assays
Susceptibility profiles of pandemic and seasonal influenza A/
H1N1 strains as well as recombinant pH1N1 viruses against
oseltamivir carboxylate (Hoffmann La Roche, Basel, Switzerland),
zanamivir (GlaxoSmithKline, Stevenage, UK), peramivir (Bio-
Cryst, Birmingham, AL) and A-315675 (Abbott Laboratories,
North Chicago, IL) were determined by NA inhibition assays
using methylumbelliferyl-N-acetyl neuraminic acid (MUNANA,
Sigma, St. Louis, MO) as a fluorescent substrate [40].
Generation of recombinant pH1N1 viruses
The eight segments of pandemic influenza A/H1N1 virus (A/
Quebec/141447/09) were amplified by RT-PCR and inserted
into the recently-described bidirectional pLLB-A/G expression/
translation plasmids by recombination in E. coli [41]. The pLLBA
plasmid containing the NA segment was used in PCR-mediated
site-directed mutagenesis kit (Stratagene, La Jolla, CA) for the
introduction of the H274Y mutation. Plasmids were then used to
cotransfect 293T cells for the rescue of recombinant viruses as
previously described [42].
Viral genome sequencing and evaluation of viral
quasispecies
RNA was isolated directly from human nasopharyngeal
aspirates or mouse lungs by using the QIAamp Viral RNA kit
(Qiagen, Mississauga, ON, Canada). Complementary DNA
(cDNA) was synthesized by using 500 ng of the influenza specific
Uni12 primer [43] and the SuperScript II reverse transcriptase
(GIBCO-BRL, Burlington, ON, Canada). Viral cDNA was used
to amplify the eight influenza viral segments by PCR using the Pfu
Turbo Polymerase (Stratagene, La Jolla, CA) and primers specific for
each influenza gene [43]. PCR products were gel-purified and
sequenced using an automated DNA sequencer (ABI Prism 377
DNA sequencer, Applied Biosystems, Foster City, CA). For
evaluation of viral quasispecies, cDNAs of the NA gene from the
original clinical samples were cloned into the pJET vector
(Fermentas, Burlington, ON). Sixteen clones were sequenced to
establish the ratios of WT and mutant populations within each
clinical strain.
In vitro replication experiment
ST6Gal I-expressing MDCK cells (kindly provided by Dr. Y.
Kawaoka, University of Wisconsin, WI) [44] were infected at a
multiplicity of infection (MOI) of 0.001 with pandemic or seasonal
A/H1N1 viruses (A/Brisbane/59/2007) containing or not the
H274Y NA mutation. Supernatants were serially collected post-
infection and assayed for numbers of PFUs using standard plaque
assays.
Mouse studies
Six to eight week old female BALB/c mice (Charles River, ON,
Canada) were used to evaluate weight loss as well as lung viral
titers, cytokines transcript levels and histopathological changes
following pH1N1 infection. Anesthetized mice were challenged by
intranasal inoculation of 5610
5 PFUs in 50 ml virus diluent
(Minimal Essential Media (MEM), 0.3% Bovine Serum Albumin
(BSA), penicillin/streptomycin) of the WT or H274Y mutant
influenza virus isolate. After challenge, animals were weighed daily
for 12 days and monitored for clinical signs. On days 1, 3, 6 and 9
post-infection (days varied according to the experiment), 3 mice
per group were sacrificed and lung tissue was placed into
RNAlater (Qiagen) for RNA preservation and subsequent RNA
extraction. Additional samples of fresh tissues were immediately
frozen for viral isolation. All procedures were approved by the
Institutional Animal Care Committee at the National Microbiol-
ogy Laboratory (NML) of the Public Health Agency of Canada
(PHAC) according to the guidelines of the Canadian Council on
Animal Care. All infectious work was performed in biocontain-
ment level 4 at the NML.
Lung tissues were harvested during necropsies and homoge-
nized in MEM/BSA using a bead mill homogenizer (Tissue Lyser,
Qiagen). Debris was pelleted by centrifugation (2,000 g, 5 min)
and 10-fold serial dilutions of supernatant were plated on MDCK
cells with six replicates per dilution. At 72–96 h post-infection, the
plates were scored for cytopathic effects (CPE) and the TCID50
virus titers were calculated using the method of Reed and Muench
[45]. Tissues preserved in RNAlater were homogenized using a
bead mill homogenizer and RNA was isolated using the RNeasy
Mini Kit (Qiagen). Pandemic H1N1 copy numbers were
determined by Q-RT-PCR using the LightCycler 480 RNA
Master Hydrolysis Probes (Roche Diagnostics, Laval, QC) assay
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number GQ160606). Reaction conditions were the following:
63uC – 3 min, 95uC – 30 s and cycling of 95uC – 15 s, 60uC–
30 s for 45 cycles using a Lightcycler 480 (Roche). The lower
detection limit for this pH1N1 assay is 0.1 PFU/ml. The primer/
probe sequences are as follow: HAForward– GGATCAA-
GAAGGGAGAATGAACTATT; HAReverse – AATGCA-
TATCTCGGTACCACTAGATTT and HAProbe (TET) –
CCGGGAGACAAAA-TAACATTCGAAGCAAC.
For measuring cytokines expression on days 1, 6 and 9,
extracted RNA was first analyzed with the RNA 6000 Nano
LabChip and Bioanalyser (Agilent, Switzerland). cDNA was
prepared using RNA of standardized quality (RIN.8) and
quantity (3.68 mg of total RNA), the Superscript II RNase H
(Invitrogen, Burlington, ON, Canada) and 250 ng of random
primer hexamers (Invitrogen). Equal amounts of cDNA were run
in triplicate and amplified/detected using the Amplifluor Uni-
Primer system (Applied Biosystem, Foster City, CA) in which the
forward or the reverse primers are tailed with the Z sequence 59-
ACTGAACCTGACCGTACA. The results were normalized
based on amplification of an internal gene (18S ribosome) and
amounts of target gene were calculated according to a standard
curve. The primer sequences for the cytokines/chemokines IL-4,
IL-5, IL-6, IL-10, KC, MCP-1, MIP-1a and IFN-c are available
upon request [46].
For lung histopathological studies, one pulmonary lobe was
removed at serial times and fixed with 10% buffered formalin.
Tissues were embedded in paraffin, sectioned in slices of 4 mm and
stained with hematoxylin-eosin. The histopathological scores
(HPS) were determined by two independent pathologists with
experience in pulmonary pathology who were unaware of the
infection status of the animals. A semi-quantitative scale was used
to score bronchial/endobronchial, peribronchial, perivascular,
interstitial, pleural and intra-alveolar inflammation [47]. Capillary
vascular congestion and pulmonary edema were also evaluated
using a semi-quantitative scale and the inflammatory cellular
infiltrate was characterized to determine if the inflammation was
acute (neutrophilic) or chronic (lymphohistiocytic).
Ferret virulence studies
Groups of five male ferrets (900–1500 g) (Triple F Farms, Sayre,
PA) were lightly anesthetized by isoflurane and received by
intranasal instillation 250 ml (125 ml/nare) of PBS containing
4.5log TCID50/ml of pH1N1 viruses with or without the H274Y
NA mutation. Telemetric transmitters (DST micro-T, Star-Oddi,
Iceland) were subcutaneously implanted and temperature profiles
of ferrets were recorded every 15 min starting 2 days prior and up
to 14 days post-inoculation. Ferrets were weighed daily and nasal
wash samples were collected from animals on a daily basis during
14 days post-inoculation by instillation of 5 ml of PBS into the
external nares of the animals. The work was performed in
biocontainment level 2+ according to procedures approved by the
Institutional Animal Care Committee of Armand Frapier Institute.
Virus titers were determined by standard plaque assays using
ST6Gal I-expressing MDCK cells. In addition, serum was also
collected from each ferret before intranasal infection and on day
14 post-infection to evaluate specific antibody levels against the
pH1N1 A/California/07/2009 and the seasonal A/Brisbane/59/
2007 strains using standard hemagglutination inhibition assays.
For transcripts analysis of IL-2, IL-6, IL-12 and IFN-c on day
14 post-infection, RNA was isolated from retropharyngeal lymph
nodes using the RNAqueous Micro (Ambion, Streetsville, Ontario)
and cDNA was generated with the Transcriptor First Strand
cDNA Synthesis Kit (Roche). Amplification of cytokine cDNA was
performed as previously described [48]. The results were
normalized based on amplification of an internal gene (GAPDH).
Ferret transmission studies
Five male ferrets (900–1500 g) (Triple F Farms, Sayre, PA) were
lightly anesthetized by isoflurane and received by intranasal
instillation 250 ml (125 ml/nare) of PBS containing 4.5log
TCID50/ml of pH1N1 virus with the H274Y NA mutation. Each
ferret was placed individually in a cage. Approximately 24 h
following viral infection, inoculated-contact animal pairs were
established by placing a naı ¨ve ferret into each cage allowing the
exchange of respiratory droplets by direct contact. Inoculated and
contact animals were monitored for clinical signs and nasal wash
samples were collected for viral titers every day over a 14-day
period. Serum was also collected from each ferret before intranasal
infection and on day 14 post-infection to evaluate specific antibody
levels against the pH1N1 A/California/07/2009 virus using
standard hemagglutination inhibition assays. All ferrets were
seronegative for pH1N1 A/California/07/2009 before intranasal
infection.
Statistical analyses
Paired and unpaired t test analyses were done to compare the
mutant and WT virus characteristics during in vitro and in vivo
studies, respectively.
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Figure S1 Lung viral titers of mice infected with wild-type (WT)
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TIF)
Figure S2 Lung cytokines/chemokines expression in mice
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Figure S4 Weight loss of ferrets infected with wild-type (WT) or
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TIF)
Table S1 Hemagglutination inhibition titers for pH1N1 (A/
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